Genmab (GMAB) said Monday that data from a phase 1/2 Rainfol-01 trial demonstrated that rinatabart sesutecan in combination with bevacizumab was tolerable and showed no new safety signals in patients with advanced ovarian cancer.
The most common treatment-emergent adverse events, or TAEs, under the 40-patient trial included nausea, fatigue, anemia, and neutropenia. Serious TAEs occurred in six patients, while TAEs leading to rinatabart sesutecan dose reductions occurred in 11 patients and bevacizumab discontinuation occurred in two patients, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments